A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol
Nicholas F. Brown(University College Hospital), Paul Mulholland(University College London Hospitals NHS Foundation Trust), Leena Elhussein(University of Oxford), Jane Holmes(University of Manchester), Sarah P. Blagden(Churchill Hospital), Tim Maughan(Velindre Cancer Centre), Claire Brooks(Cancer Research UK Technology), T. J. Coutts(University of Oxford), Corran Roberts(Nuffield Orthopaedic Centre), Stasya Ng(University of Oxford), Peter Hoskin(Manchester Academic Health Science Centre)
Cited by 51
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies
|Clinical and Translational Radiation Oncology|2018|932